Advanced Search

Submit Online

Review

        Next >  
Prospects for PARG inhibitors in cancer therapy
Yangchan Hu1,2 , Yuxin Meng1,2 , Zirui Zhuang2,3 , Yuancong Li1,2 , Junjun Nan1,2 , Ning Xu4 , Zu Ye5,6,* , Ji Jing2,6,*
1College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
2Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China
3School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences (UCAS), Hangzhou 310024, China
4Institute of Drug Development & Chemical Biology, College of Pharmaceutical Science, Zhejiang University of Technology, Huzhou 313200, China
5Gastric Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HlM), Chinese Academy of Sciences, Hangzhou 310022, China
6Zhejiang Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer, Hangzhou 310022, China
*Correspondence to:Ji Jing , Email:jingji@him.cas.cn Zu Ye , Email:yezuqscx@zju.edu.cn
J Mol Cell Biol, Volume 16, Issue 11, November 2024, mjae050,  https://doi.org/10.1093/jmcb/mjae050
Keyword: PARG, PARG inhibitor, cancer therapy

Poly(ADP-ribose) glycosylhydrolase (PARG) is an enzyme involved in hydrolyzing the ribose–ribose bonds present in poly(ADP-ribose) (PAR), which are primarily found in the nucleus. Along with poly(ADP-ribose) polymerase, PARG regulates the level of PAR in cells, playing a crucial role in DNA maintenance and repair processes. Recent studies have revealed elevated levels of PARG in various cancers, such as breast, liver, prostate, and esophageal cancers, indicating a link to unfavorable cancer outcomes. PARG is a significant molecular target for treating PAR-related cancers. This review provides a comprehensive overview of the physiological role of PARG and the development of its inhibitors, highlighting its potential as an innovative target for cancer treatment.


Volume 16, Issue 11
November 2024